No FDA panel bodes well for Pfizer's palbociclib
This article was originally published in Scrip
Shares of Pfizer got about a 2.5% boost on 8 January after the company disclosed the FDA currently has no plans to convene its Oncologic Drugs Advisory Committee (ODAC) to scrutinize the new drug application (NDA) for palbociclib – news that had some on Wall Street speculating the pharma giant could win an earlier-than-expected approval of the experimental breast cancer medicine.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.